MedPath

Exploring the Landscape of Optic Neuropathy and Vasculopathy: the LOVE study

Not Applicable
Conditions
Optic neuropathy in individuals with diabetes
Eye Diseases
Registration Number
ISRCTN99411112
Lead Sponsor
ational Sun Yat-sen University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing
Sex
All
Target Recruitment
1200
Inclusion Criteria

1. Community-registered patients with diabetes
2. Individuals who live in Guangzhou for more than 6 months
3. Aged 18 years and older
4. Individuals who are capable of cooperating with ocular examinations and meeting quality standards
5. Individuals who voluntarily participate in this study
6. Individuals who do not participate in other trials or treatments aimed at preventing or delaying the onset and progression of diabetic retinopathy (DR)
7. Absence of retinal lesions, or retinal/macular lesions not meeting the positive criteria for referable DR

Exclusion Criteria

1. Individuals who cannot cooperate with examinations

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ongitudinal change of peripapillary retinal nerve fiber layer thickness measured using optical coherence tomography (OCT) in eligible participants at baseline and each follow-up visit (2 and 4 years)
Secondary Outcome Measures
NameTimeMethod
1. Longitudinal change of macular ganglion cell-inner plexiform layer (GCIPL) thickness measured using optical coherence tomography (OCT) in eligible participants at baseline and each follow-up visit (2 and 4 years)<br>2. Longitudinal change of macular ganglion cell complex (GCC) thickness measured using OCT in eligible participants at baseline and each follow-up visit (2 and 4 years)<br>3. Longitudinal change of macular microcirculation measured using optical coherence tomography angiography (OCTA) in eligible participants at baseline and each follow-up visit (2 and 4 years)<br>4. Longitudinal change of microcirculation in optic nerve head measured using OCTA in eligible participants at baseline and each follow-up visit (2 and 4 years)
© Copyright 2025. All Rights Reserved by MedPath